Investing.com -- Kala Pharmaceuticals Inc (NASDAQ:KALA) stock dropped 6.7% Friday after the company announced the closing of its previously announced registered direct offering that raised approximately $10 million.
The biopharmaceutical company sold 10 million shares of common stock (or pre-funded warrants in lieu thereof) at a price of $1.00 per share in an at-the-market offering under Nasdaq rules. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.
Kala intends to use the net proceeds from the offering to repay certain of its outstanding debt and for general corporate purposes, according to the company’s statement. The final proceeds amount will be reduced by placement agent fees and other offering expenses.
The share offering, while providing needed capital, has diluted existing shareholder value, contributing to the stock’s decline in Friday’s trading session.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








